A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab

Vasculitic immune checkpoint inhibitor-related adverse events (irAEs) are rare, with limited data to guide their management. Here, we present a case of a 67-year-old female with stage IV cutaneous melanoma who received first-line pembrolizumab. She had completed 21 cycles of pembrolizumab dosed at 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloomer, Chance H., Annabathula, Rahul V., Aggarwal, Vanya, Upadhya, Bharathi, Lycan, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581648/
https://www.ncbi.nlm.nih.gov/pubmed/36277471
http://dx.doi.org/10.1155/2022/7971169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581648/
https://www.ncbi.nlm.nih.gov/pubmed/36277471
http://dx.doi.org/10.1155/2022/7971169

Ejemplares similares